



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 October 2026
EMADOC-1700519818-3505038
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Kyinsu

insulin icodec / semaglutide

On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Kyinsu. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S.

The CHMP adopted a change to the existing indication, as follows:²

Kyinsu is indicated for the treatment of adults with **insufficiently controlled** type 2 diabetes mellitus ~~insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists~~ as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products.

For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold, removed text as strikethrough

